Soligenix begins Phase III of dusquetide to treat oral mucositis

Soligenix Inc. (NASDAQ:SNGX) began the Phase III IDR-OM-02 (DOM-INNATE) trial of dusquetide (SGX94, SGX942) to treat severe oral mucositis (OM) in about 190 patients undergoing chemoradiation therapy (CRT) for head and

Read the full 317 word article

How to gain access

Continue reading with a
two-week free trial.